Latest Alcidion (ASX:ALC) News

Alcidion confirms FY26 revenue above $50 million and EBITDA over $5 million, completing the Kyra flow products acquisition from Telstra Health to expand its patient flow solutions in ANZ and the UK.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Alcidion Group has acquired Telstra Health's Kyra flow products for $3 million upfront, adding 33 long-term customers and boosting recurring revenue in key Australian states.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.

Alcidion Group Limited has reported a robust half-year performance with a 44% revenue increase and a return to profitability, driven by key contract expansions and new wins in the UK and Australia. The company is now positioned to secure a major Electronic Patient Record contract with University Hospitals Sussex NHS Foundation Trust.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

Alcidion Group has been named preferred supplier for a major UK hospital's Electronic Patient Record system, driving a 40% jump in contracted revenue and a robust cash position in Q2 FY26.

Alcidion has been named the preferred supplier for University Hospitals Sussex's new Electronic Patient Record system, with a contract expected to exceed A$35 million over seven years. This deal builds on an existing partnership and marks a significant expansion for Alcidion in the UK healthcare IT market.